[MO45] Mini-Oral Session 45　Lung Cancer / Thoracic Cancer 8（EGFR-TKI 2）
【E】

[MO45-5] Impact of PD-L1 expression on osimertinib efficacy in untreated EGFR-mutated NSCLC: a prospective observational study

^○Naoya Nishioka^1,2, Tadaaki Yamada², Akihiro Yoshimura², Yusuke Okuma^3,4, Akito Fukuda^3,4, Satoshi Watanabe⁵, Takayuki Takeda⁶, Yusuke Chihara⁷, Shinosuke Takemoto⁸, Taishi Harada⁹, Osamu Hiranuma¹⁰, Yukina Shirai¹¹, Akihiro Nishiyama¹², Seiji Yano¹², Yasuhiro Goto¹³, Shinsuke Shiotsu¹⁴, Kei Kunimasa¹⁵, Hirotsugu Kenmotsu¹, Toshiaki Takahashi¹, Koichi Takayama² (1.Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, 2.Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 3.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 4.Department of Thoracic Oncology, National Cancer Center Hospital, 5.Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medicine and Dental Hospital, 6.Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, 7.Department of Respiratory Medicine, Uji-Tokushukai Medical Center, 8.Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 9.Department of Medical Oncology, Fukuchiyama City Hospital, 10.Department of Medical Oncology, Fukuchiyama City Hospital, 11.Department of Respiratory Medicine, Juntendo University, 12.Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13.Department of Respiratory Medicine, Fujita Health University School of Medicine, 14.Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15.Department of Thoracic Oncology, Osaka International Cancer Institution)